Author(s):
Raimundo, Pedro 
; Miranda, A ; Ribeiro, J ; Mansinho, Kamal
Date: 2010
Origin: Acta Médica Portuguesa
Document details
Cardiovascular risk in HIV infected patients.
Description
The increased cardiovascular risk has been implicated in both HIV infection and antirretroviral therapy. The endothelial dysfunction triggered by the infection and the metabolic abnormalities associated with therapy predispose to premature atherosclerosis. The recognition of the increased cardiovascular risk in these patients will allow more appropriate prevention strategies, as well as therapy optimization with lipid-lowering agents and antirretroviral therapy modification. The increased cardiovascular risk has been implicated in both HIV infection and antirretroviral therapy. The endothelial dysfunction triggered by the infection and the metabolic abnormalities associated with therapy predispose to premature atherosclerosis. The recognition of the increased cardiovascular risk in these patients will allow more appropriate prevention strategies, as well as therapy optimization with lipid-lowering agents and antirretroviral therapy modification.
The increased cardiovascular risk has been implicated in both HIV infection and antirretroviral therapy. The endothelial dysfunction triggered by the infection and the metabolic abnormalities associated with therapy predispose to premature atherosclerosis. The recognition of the increased cardiovascular risk in these patients will allow more appropriate prevention strategies, as well as therapy optimization with lipid-lowering agents and antirretroviral therapy modification. The increased cardiovascular risk has been implicated in both HIV infection and antirretroviral therapy. The endothelial dysfunction triggered by the infection and the metabolic abnormalities associated with therapy predispose to premature atherosclerosis. The recognition of the increased cardiovascular risk in these patients will allow more appropriate prevention strategies, as well as therapy optimization with lipid-lowering agents and antirretroviral therapy modification.
Document Type
Article
Language Portuguese
Language Portuguese
| Financiadores do RCAAP | |||||||
|
|
|
|
|
|
||